Ann: Appendix 4E & Preliminary Final Report, page-75

FYI Buckland, here's our history with Nihon Nohyaku

30 March 2015 - A Joint Patent issued following a research collaboration which began in July 2013. Patent Number: WO/2015/037747 - some 50 analogues of monepantel, synthesised by Nihon Nohyaku Co Ltd (NNC) and tested for anticancer activity by PharmAust. Epichem synthesised and optimised a number of these AAD candidates from the NNC library for screening in anti-cancer assays

6 Sept 2017 - NNC assigned it interests in the joint patent portfolio to PharmAust, in return for a royalty % on sales. PharmAust now owns the rights to these 50+ novel AAD compounds. Other than NNC, PharmAust is not aware of any third party interests impinging on these intellectual property rights.

The portfolio consists of 2 patent families of aminoacetonitrile compounds (AADs) - related to, but distinct from Monepantel. We have the right to develop these for any use, completely separate of Elanco involvement. I think we'll eventually pursue some of these but as an add-on to our Elanco monepantel collaborations ... which are top priority.